OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology

Figure_1 Figure 1: Clinical Remission rate observed in all-comers population and sub-population according to composite IL7R axis biomarker in CoTikiS phase 2 study. OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab development, leveraging a new predictive biomarker.Leads a new era in cancer vaccines with Tedopi® on track for registration.Drives company transfo ...